Valuation: Fulgent Genetics, Inc.

Market Cap 548M 470M 439M 402M 755M 52.44B 765M 5.19B 2.02B 26.34B 2.06B 2.01B 87.14B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 548M 470M 439M 402M 755M 52.44B 765M 5.19B 2.02B 26.34B 2.06B 2.01B 87.14B EV / Sales 2026 *
1.65x
EV / Sales 2027 * 1.43x
Free-Float
48.81%
Yield 2026 *
-
Yield 2027 * -
1 day-0.10%
1 week+7.22%
Current month+20.24%
1 month+0.10%
3 months+14.50%
6 months-13.52%
Current year-24.25%
1 week 18.28
Extreme 18.28
20.52
1 month 16.05
Extreme 16.0501
20.52
Current year 13.46
Extreme 13.46
28.95
1 year 13.46
Extreme 13.46
31.04
3 years 13.46
Extreme 13.46
34.64
5 years 13.46
Extreme 13.46
109.55
10 years 2.72
Extreme 2.725
189.89
Manager TitleAgeSince
President 59 02/05/2022
Chief Executive Officer 70 12/05/2016
Director of Finance/CFO 58 31/12/2015
Director TitleAgeSince
Chairman 70 31/08/2016
Director/Board Member 76 31/07/2019
Director/Board Member 57 31/07/2022
Date Insider Type Main position Quantity % Market Cap.
26/07/26 Tax

Chief Financial Officer

-2,747 0.0090%
26/07/26 Tax

Founder

-4,361 0.0142%
26/07/26 Tax

Chief Technology Officer

-1,645 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
-0.10%+7.22%-6.99%-40.61% 548M
+2.21%+7.13%+105.02%+504.57% 46.82B
+1.06%+5.72%+21.62%+55.98% 26.99B
-1.40%-5.89%-26.65%-35.28% 7.52B
-0.30%+0.62%+11.97%+151.54% 6.06B
+0.25%-3.77%+9.78%+68.98% 3.3B
+5.47%+11.51%-27.88%+1,776.40% 2.46B
+2.72%+6.52%+174.76%+20.60% 2.12B
+1.92%+2.65%+2.35%-50.31% 2.12B
+2.36%+2.47%+34.39%+22.01% 1.9B
Average +1.42%+1.61%+29.84%+247.39% 9.99B
Weighted average by Cap. +1.49%+2.70%+57.83%+303.93%

Financials

2026 *2027 *
Net sales 332M 284M 266M 243M 457M 31.74B 463M 3.14B 1.22B 15.94B 1.25B 1.22B 52.73B 383M 328M 307M 281M 527M 36.62B 534M 3.62B 1.41B 18.39B 1.44B 1.41B 60.84B
Net income -112M -95.94M -89.77M -82.17M -154M -10.72B -156M -1.06B -414M -5.38B -421M -411M -17.81B -79M -67.67M -63.32M -57.96M -109M -7.56B -110M -748M -292M -3.8B -297M -290M -12.56B
Net Debt - -
Logo Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Employees
1,315
Date Price Change Volume
21/08/26 US$19.90 -0.10% 323,956
20/08/26 US$19.92 +0.91% 203,680
19/08/26 US$19.74 +6.30% 264,961
18/08/26 US$18.57 -0.48% 167,973
17/08/26 US$18.66 +0.54% 242,915
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
19.92USD
Average target price
19.00USD
Spread / Average Target
-4.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FLGT Stock